Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 555-562

  Milling, Simon W F ^a,b   Sai, Tao ^a,c   Silvers, Willys K ^a   Mintz, Beatrice ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Morphotek Inc   (United States)

Author keywords

Dendritic cells; Rodent; T lymphocytes; Transgenic; Tumour immunity

Indexed keywords

BETA INTERMEDIN; CD11B ANTIGEN; CD16 ANTIGEN; CD32 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CD8ALPHA ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; IMMUNOGLOBULIN G; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SIMIAN VIRUS 40; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 13544270172     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00019     Document Type: Article

References (36)

1. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991; 97:197-202.
2. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71:142-147.
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
4. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
5. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18:245-273.
6. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-1111.
7. Bradl M, Klein-Szanto A, Porter S, Mintz B. Malignant melanoma in transgenic mice. Proc Natl Acad Sci USA 1991; 88:164-168.
8. Mintz B, Silvers WK. Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci USA 1993; 90:8817-8821.
9. Mintz B, Silvers WK, Klein-Szanto AJ. Histopathogenesis of malignant skin melanoma induced in genetically susceptible transgenic mice. Proc Natl Acad Sci USA 1993; 90:8822-8826.
10. Milling SWF, Silvers WK, Sai T, Mintz B. Decline in MHC class I expression with increasing thickness of cutaneous melanomas in standard-strain transgenic mouse models. Melanoma Res 2002; 12:221-230.
11. Sai T, Milling SWF, Mintz B. Freezing and thawing of bone marrow-derived murine dendritic cells with subsequent retention of immunophenotype and of antigen processing and presentation characteristics. J Immunol Methods 2002; 264:153-162.
12. Le Fur N, Kelsall SR, Mintz B. Base substitution at different alternative splice donor sites of the tyrosinase gene in murine albinism. Genomics 1996; 37:245-248.
13. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-3519.
14. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-1009.
15. Kawakami Y. Immunotherapy using T cell defined tumor antigens for melanoma. Microbiol Immunol 1998; 42:803-813.
16. Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997; 20:15-25.
17. Le Fur N, Kelsall SR, Silvers WK, Mintz B. Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy. Proc Natl Acad Sci USA 1997; 94:5332-5337.
18. Kelsall SR, Le Fur N, Mintz B. Qualitative and quantitative catalog of tyrosinase alternative transcripts in normal murine skin melanocytes as a basis for detecting melanoma-specific changes. Biochem Biophys Res Commun 1997; 236:173-177.
19. b molecules is controlled by dominant negative elements at peptide non-anchor residues. J Biol Chem 1996; 271:17 829-17 836.
20. Stryhn A, Pedersen LO, Romme T, Holm CB, Holm A, Buus S. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur J Immunol 1996; 26:1911-1918.
21. Rock KL, Gramm C, Benacerraf B. Low temperature and peptides favor the formation of class I heterodimers on RMA-S cells at the cell surface. Proc Natl Acad Sci USA 1991; 88:4200-4204.
22. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693-1702.
23. Rock KL, Fleischacker C, Gamble S. Peptide-priming of cytolytic T cell immunity in vivo using beta2-microglobulin as an adjuvant. J Immunol 1993; 150:1244-1252.
24. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000; 6:829-837.
25. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192:1637-1643.
26. Eggert AO, Becker JC, Ammon M, McLellan AD, Renner G, Merkel A, et al. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 2002; 32:122-127.
27. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. Immunology 1996; 156:2918-2926.
28. Yang S, Darrow TL, Vervaert CE, Seigler HF. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell Immunol 1997; 179:84-95.
29. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000; 60:6391-6395.
30. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001; 61:2062-2070.
31. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24:363-373.
32. Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131-138.
33. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91:9461-9465.
34. + T cells in the antitumor immune response. J Exp Med 1998; 188:2357-2368.
35. + T lymphocytes. Proc Natl Acad Sci USA 1999; 96:2982-2987.
36. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004; 64:2865-2873.